What is the 13F Pro Quality Score for CRBU?

13F Pro ranks Caribou Biosciences, Inc. (CRBU) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRBU's current score at https://13fpro.ai/company/CRBU (free sign-up required for the full ranking).

Which hedge funds own the most CRBU stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRBU include BlackRock,, PFIZER, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CRBU as soon as new 13F filings post.

Where does 13F Pro source CRBU data?

All Caribou Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Caribou Biosciences, Inc. files with the SEC under CIK 1619856. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRBU in?

Caribou Biosciences, Inc. (CRBU) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRBU research updated on 13F Pro?

CRBU's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Caribou Biosciences, Inc.(CRBU)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1619856 CRBU stock profile & AI dashboard →

13F Pro Quality Score

11.7/100

Rank #2,899 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

0.7/100

Profitability

2.3/100

Balance Sheet

2.9/100

Earnings Quality

12.5/100

Free Cash Flow

1.8/100

Institutional Flow

83.6/100

Revenue Scale

2.2/100

Dilution Risk

2.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CRBU Scores 12/100

exact factor attribution · 2026-09-11

CRBU's composite is driven by earnings growth and institutional flow, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.3 pts

95th pct

Institutional flow

+1.7 pts

84th pct

Shareholder dilution

-2.4 pts

3th pct

Earnings quality

-3.8 pts

13th pct

Capital efficiency

-4.7 pts

3th pct

Profitability

-7.2 pts

2th pct

Scale

-7.2 pts

2th pct

Free cash flow

-7.2 pts

2th pct

Revenue growth

-9.9 pts

1th pct

Latest change (2026-08-13): 6 → 10 · ↑ Revenue growth 2→17

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CRBU Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Caribou Biosciences, Inc. (CRBU), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRBU at 11.7/100 on a 32-signal composite quality model, placing it at rank #2,899 of 2,962 stocks — the bottom half of the AI-ranked universe. CRBU scores in the top quartile across institutional flow (83.6). Areas of concern include revenue growth (0.7) and free cash flow (1.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Caribou Biosciences, Inc. reports quarterly revenue of $1.5M, net income of $-24.3M, free cash flow of $-22.8M. Top institutional holders of CRBU by reported 13-F value include BlackRock, PFIZER, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CRBU trades on the Nasdaq exchange and files with the SEC under CIK 1619856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRBU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Caribou Biosciences, Inc. directly from SEC EDGAR. Caribou Biosciences, Inc.'s 13F Pro composite quality score has ranged between 4 and 29 since 2022, currently 11.7 — a stable long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about Caribou Biosciences, Inc.

Quirks, history, and lore behind CRBU — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in Berkeley, California.
2
The Numbers
Annual revenue is in the low tens of millions — mostly from licensing and collaborations — while it burns cash developing therapies it hopes will one day dwarf that figure.
3
The History
Founded around 2011 and built on intellectual property spun out of academic research at UC Berkeley, the same institution that gave the world some of the most influential gene-editing science ever published.
4
The Secret
Its core platform uses CRISPR-Cas12a — a lesser-known variant of the famous gene-scissors — which its scientists argue offers precision advantages over the more widely publicized Cas9 cousin.
5
The Lore
The company shares its gene-editing heritage with Jennifer Doudna's orbit — the Nobel-winning UC Berkeley lab that essentially ignited the modern CRISPR revolution — giving it serious scientific street cred from day one.
6
The Giveaway
Its name pairs a large North American deer with the word Biosciences — and its pipeline targets blood cancers and other diseases using its proprietary chRDNA gene-editing technology.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$1.5M

Net Income

Q2 2026

$-24.3M

Free Cash Flow

Q2 2026

$-22.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+11.7% YoY

$11.2MFY 2025

FY22 $13.9MFY23 $34.5MFY24 $10.0MFY25 $11.2M

Net Income

+0.7% YoY

$-148.1MFY 2025

FY22 $-99.4MFY23 $-102.1MFY24 $-149.1MFY25 $-148.1M

Operating Income

+11.0% YoY

$-148.3MFY 2025

FY22 $-106.4MFY23 $-116.1MFY24 $-166.6MFY25 $-148.3M

EPS (Diluted)

+3.6% YoY

$-1.59FY 2025

FY22 $-1.64FY23 $-1.38FY24 $-1.65FY25 $-1.59

Total Assets

-44.0% YoY

$175.4MFY 2025

FY22 $373.8MFY23 $432.2MFY24 $313.3MFY25 $175.4M

Op. Cash Flow

+19.7% YoY

$-111.0MFY 2025

FY22 $-91.0MFY23 $-93.3MFY24 $-138.2MFY25 $-111.0M

Free Cash Flow

+21.5% YoY

$-112.4MFY 2025

FY22 $-97.4MFY23 $-104.9MFY24 $-143.1MFY25 $-112.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$11.2M +11.7%	$10.0M -71.0%	$34.5M +148.9%	$13.9M +44.3%	$9.6M -22.4%	$12.4M
Net Income	$-148.1M +0.7%	$-149.1M -46.1%	$-102.1M -2.7%	$-99.4M -48.6%	$-66.9M -95.1%	$-34.3M
Operating Income	$-148.3M +11.0%	$-166.6M -43.6%	$-116.1M -9.1%	$-106.4M -58.9%	$-67.0M -85.4%	$-36.1M
EPS (Diluted)	$-1.59 +3.6%	$-1.65 -19.6%	$-1.38 +15.9%	$-1.64 +22.3%	$-2.11	—
Total Assets	$175.4M -44.0%	$313.3M -27.5%	$432.2M +15.6%	$373.8M -15.5%	$442.4M +1127.2%	$36.0M
Operating Cash Flow	$-111.0M +19.7%	$-138.2M -48.1%	$-93.3M -2.6%	$-91.0M -179.7%	$-32.5M +2.1%	$-33.2M
Free Cash Flow	$-112.4M +21.5%	$-143.1M -36.4%	$-104.9M -7.7%	$-97.4M -181.2%	$-34.6M -3.3%	$-33.5M

Get alerted when CRBU's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Caribou Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRBU

BlackRock, Inc.
$13.8M7,815,843 sh
PFIZER INC
$7.9M4,690,431 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.4M4,208,568 sh
MACKENZIE FINANCIAL CORP
$6.4M3,650,796 sh
RENAISSANCE TECHNOLOGIES LLC
$4.9M2,773,545 sh
Kynam Capital Management, LP
$4.4M2,503,302 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.2M2,374,894 sh
ACADIAN ASSET MANAGEMENT LLC
$3.1M1,774,474 sh
STATE STREET CORP
$2.9M1,632,914 sh
BANK OF AMERICA CORP /DE/
$2.5M1,410,958 sh

Fund	Value	Shares
BlackRock, Inc.	$13.8M	7,815,843
PFIZER INC	$7.9M	4,690,431
VANGUARD CAPITAL MANAGEMENT LLC	$7.4M	4,208,568
MACKENZIE FINANCIAL CORP	$6.4M	3,650,796
RENAISSANCE TECHNOLOGIES LLC	$4.9M	2,773,545
Kynam Capital Management, LP	$4.4M	2,503,302
GEODE CAPITAL MANAGEMENT, LLC	$4.2M	2,374,894
ACADIAN ASSET MANAGEMENT LLC	$3.1M	1,774,474
STATE STREET CORP	$2.9M	1,632,914
BANK OF AMERICA CORP /DE/	$2.5M	1,410,958

Companies Similar to CRBU

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

PRLD

Prelude Therapeutics Inc

AI score

Similar quality profile · 2 shared holders

Kynam Capital Management, LP Spark Investment Management LLC

DNA

Ginkgo Bioworks Holdings, Inc.

AI score

Similar quality profile · 6 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Susquehanna Portfolio Strategies, LLC Green Alpha Advisors, LLC

WVE

Wave Life Sciences, Inc.

AI score

Similar quality profile · 6 shared holders

PFIZER INC MAVERICK CAPITAL LTD Susquehanna Portfolio Strategies, LLC

ARCT

Arcturus Therapeutics Holdings Inc.

AI score

Similar quality profile · 6 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Green Alpha Advisors, LLC Susquehanna Portfolio Strategies, LLC

BIOA

BioAge Labs, Inc.

AI score

Similar quality profile · 3 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC China Universal Asset Management Co., Ltd.GF FUND MANAGEMENT CO. LTD.

IMA

ImageneBio, Inc.

AI score

Similar quality profile · 1 shared holders

NANO CAP NEW MILLENNIUM GROWTH FUND L P

ALEC

Alector, Inc.

AI score

Similar quality profile · 5 shared holders

Kynam Capital Management, LP JACOBS LEVY EQUITY MANAGEMENT, INC NANO CAP NEW MILLENNIUM GROWTH FUND L P

STRO

SUTRO BIOPHARMA, INC.

AI score

Similar quality profile · 3 shared holders

Kynam Capital Management, LP RBF Capital, LLC Point72 Asia (Singapore) Pte. Ltd.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRBU on your watchlist

Track score changes the day Caribou Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRBU a good stock to buy?

13F Pro's AI-powered analysis of Caribou Biosciences, Inc. (CRBU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRBU are available on the CRBU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRBU is classified as a small company.

Which hedge funds own CRBU?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRBU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Caribou Biosciences, Inc.'s investment landscape.